- Home
- AXP vs AZN Comparison
AXP vs AZN Comparison
Compare AXP & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXP | AZN |
|---|---|---|
| Founded | 1850 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.8B | 283.9B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | AXP | AZN |
|---|---|---|
| Price | $360.50 | $94.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 2 |
| Target Price | ★ $334.57 | N/A |
| AVG Volume (30 Days) | 2.8M | ★ 5.2M |
| Earning Date | 01-30-2026 | 02-10-2026 |
| Dividend Yield | 0.92% | ★ 1.59% |
| EPS Growth | 9.59 | ★ 45.02 |
| EPS | ★ 14.88 | 6.02 |
| Revenue | ★ $65,294,000,000.00 | $58,127,000,000.00 |
| Revenue This Year | $19.90 | $11.40 |
| Revenue Next Year | $8.96 | $6.06 |
| P/E Ratio | $24.08 | ★ $16.01 |
| Revenue Growth | 10.22 | ★ 13.52 |
| 52 Week Low | $220.43 | $61.24 |
| 52 Week High | $387.49 | $96.51 |
Technical Indicators
Market Signals| Indicator | AXP | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 59.19 |
| Support Level | $350.72 | $92.78 |
| Resistance Level | $385.13 | $96.43 |
| Average True Range (ATR) | 6.60 | 1.45 |
| MACD | -3.10 | 0.13 |
| Stochastic Oscillator | 23.86 | 77.51 |
Price Performance
Historical ComparisonAbout AXP American Express Company
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. It operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.